• Something wrong with this record ?

The Proton-Boron Reaction Increases the Radiobiological Effectiveness of Clinical Low- and High-Energy Proton Beams: Novel Experimental Evidence and Perspectives

P. Bláha, C. Feoli, S. Agosteo, M. Calvaruso, FP. Cammarata, R. Catalano, M. Ciocca, GAP. Cirrone, V. Conte, G. Cuttone, A. Facoetti, GI. Forte, L. Giuffrida, G. Magro, D. Margarone, L. Minafra, G. Petringa, G. Pucci, V. Ricciardi, E. Rosa, G....

. 2021 ; 11 (-) : 682647. [pub] 20210628

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21024495

Protontherapy is a rapidly expanding radiotherapy modality where accelerated proton beams are used to precisely deliver the dose to the tumor target but is generally considered ineffective against radioresistant tumors. Proton-Boron Capture Therapy (PBCT) is a novel approach aimed at enhancing proton biological effectiveness. PBCT exploits a nuclear fusion reaction between low-energy protons and 11B atoms, i.e. p+11B→ 3α (p-B), which is supposed to produce highly-DNA damaging α-particles exclusively across the tumor-conformed Spread-Out Bragg Peak (SOBP), without harming healthy tissues in the beam entrance channel. To confirm previous work on PBCT, here we report new in-vitro data obtained at the 62-MeV ocular melanoma-dedicated proton beamline of the INFN-Laboratori Nazionali del Sud (LNS), Catania, Italy. For the first time, we also tested PBCT at the 250-MeV proton beamline used for deep-seated cancers at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy. We used Sodium Mercaptododecaborate (BSH) as 11B carrier, DU145 prostate cancer cells to assess cell killing and non-cancer epithelial breast MCF-10A cells for quantifying chromosome aberrations (CAs) by FISH painting and DNA repair pathway protein expression by western blotting. Cells were exposed at various depths along the two clinical SOBPs. Compared to exposure in the absence of boron, proton irradiation in the presence of BSH significantly reduced DU145 clonogenic survival and increased both frequency and complexity of CAs in MCF-10A cells at the mid- and distal SOBP positions, but not at the beam entrance. BSH-mediated enhancement of DNA damage response was also found at mid-SOBP. These results corroborate PBCT as a strategy to render protontherapy amenable towards radiotherapy-resilient tumor. If coupled with emerging proton FLASH radiotherapy modalities, PBCT could thus widen the protontherapy therapeutic index.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024495
003      
CZ-PrNML
005      
20211013133911.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2021.682647 $2 doi
035    __
$a (PubMed)34262867
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bláha, Pavel $u Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Napoli, Naples, Italy
245    14
$a The Proton-Boron Reaction Increases the Radiobiological Effectiveness of Clinical Low- and High-Energy Proton Beams: Novel Experimental Evidence and Perspectives / $c P. Bláha, C. Feoli, S. Agosteo, M. Calvaruso, FP. Cammarata, R. Catalano, M. Ciocca, GAP. Cirrone, V. Conte, G. Cuttone, A. Facoetti, GI. Forte, L. Giuffrida, G. Magro, D. Margarone, L. Minafra, G. Petringa, G. Pucci, V. Ricciardi, E. Rosa, G. Russo, L. Manti
520    9_
$a Protontherapy is a rapidly expanding radiotherapy modality where accelerated proton beams are used to precisely deliver the dose to the tumor target but is generally considered ineffective against radioresistant tumors. Proton-Boron Capture Therapy (PBCT) is a novel approach aimed at enhancing proton biological effectiveness. PBCT exploits a nuclear fusion reaction between low-energy protons and 11B atoms, i.e. p+11B→ 3α (p-B), which is supposed to produce highly-DNA damaging α-particles exclusively across the tumor-conformed Spread-Out Bragg Peak (SOBP), without harming healthy tissues in the beam entrance channel. To confirm previous work on PBCT, here we report new in-vitro data obtained at the 62-MeV ocular melanoma-dedicated proton beamline of the INFN-Laboratori Nazionali del Sud (LNS), Catania, Italy. For the first time, we also tested PBCT at the 250-MeV proton beamline used for deep-seated cancers at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy. We used Sodium Mercaptododecaborate (BSH) as 11B carrier, DU145 prostate cancer cells to assess cell killing and non-cancer epithelial breast MCF-10A cells for quantifying chromosome aberrations (CAs) by FISH painting and DNA repair pathway protein expression by western blotting. Cells were exposed at various depths along the two clinical SOBPs. Compared to exposure in the absence of boron, proton irradiation in the presence of BSH significantly reduced DU145 clonogenic survival and increased both frequency and complexity of CAs in MCF-10A cells at the mid- and distal SOBP positions, but not at the beam entrance. BSH-mediated enhancement of DNA damage response was also found at mid-SOBP. These results corroborate PBCT as a strategy to render protontherapy amenable towards radiotherapy-resilient tumor. If coupled with emerging proton FLASH radiotherapy modalities, PBCT could thus widen the protontherapy therapeutic index.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Feoli, Chiara $u Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Napoli, Naples, Italy
700    1_
$a Agosteo, Stefano $u Energy Department, Politecnico di Milano, and INFN, Sezione di Milano, Milan, Italy
700    1_
$a Calvaruso, Marco $u Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù, Italy $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Cammarata, Francesco Paolo $u Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù, Italy $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Catalano, Roberto $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Ciocca, Mario $u Medical Physics Unit & Research Department, Centro Nazionale di Adroterapia Oncologica (CNAO) & INFN, Sezione di Pavia, Pavia, Italy
700    1_
$a Cirrone, Giuseppe Antonio Pablo $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Conte, Valeria $u Laboratori Nazionali di Legnaro (LNL), INFN, Legnaro, Italy
700    1_
$a Cuttone, Giacomo $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Facoetti, Angelica $u Medical Physics Unit & Research Department, Centro Nazionale di Adroterapia Oncologica (CNAO) & INFN, Sezione di Pavia, Pavia, Italy
700    1_
$a Forte, Giusi Irma $u Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù, Italy $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Giuffrida, Lorenzo $u Extreme Light Infrastructure (ELI)-Beamlines Center, Institute of Physics (FZU), Czech Academy of Sciences, Prague, Czechia
700    1_
$a Magro, Giuseppe $u Medical Physics Unit & Research Department, Centro Nazionale di Adroterapia Oncologica (CNAO) & INFN, Sezione di Pavia, Pavia, Italy
700    1_
$a Margarone, Daniele $u Extreme Light Infrastructure (ELI)-Beamlines Center, Institute of Physics (FZU), Czech Academy of Sciences, Prague, Czechia
700    1_
$a Minafra, Luigi $u Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù, Italy $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy
700    1_
$a Petringa, Giada $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy $u Extreme Light Infrastructure (ELI)-Beamlines Center, Institute of Physics (FZU), Czech Academy of Sciences, Prague, Czechia
700    1_
$a Pucci, Gaia $u Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù, Italy $u Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STeBiCeF), Università di Palermo, Palermo, Italy
700    1_
$a Ricciardi, Valerio $u Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Napoli, Naples, Italy $u Department of Mathematics & Physics, Università L. Vanvitelli, Caserta, Italy
700    1_
$a Rosa, Enrico $u Radiation Biophysics Laboratory, Department of Physics "E. Pancini", Università di Napoli Federico II, Naples, Italy
700    1_
$a Russo, Giorgio $u Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù, Italy $u Laboratori Nazionali del Sud (LNS), INFN, Catania, Italy $u The Sicilian Center of Nuclear Physics and the Structure of Matter (CSFNSM), Catania, Italy
700    1_
$a Manti, Lorenzo $u Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Napoli, Naples, Italy $u Radiation Biophysics Laboratory, Department of Physics "E. Pancini", Università di Napoli Federico II, Naples, Italy
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 11, č. - (2021), s. 682647
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34262867 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133908 $b ABA008
999    __
$a ind $b bmc $g 1708347 $s 1144992
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c - $d 682647 $e 20210628 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20211006

Find record

Citation metrics

Archiving options